Literature DB >> 1351056

Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation.

E Peles1, R Lamprecht, R Ben-Levy, E Tzahar, Y Yarden.   

Abstract

The neu protooncogene encodes a tyrosine kinase receptor that is involved in the regulation of normal growth and malignant transformation. To circumvent the use of the incompletely characterized ligand of Neu, we constructed a chimeric protein composed of the ligand-binding domain of the epidermal growth factor receptor and the transmembrane and cytoplasmic portions of Neu. By expressing this Neu-epidermal growth factor receptor chimera (termed NEC), we found that following stimulation by the heterologous ligand, the tyrosine kinase of Neu became associated with a phosphatidylinositol (PI) kinase activity. The association was dependent on the concentration of the ligand and was almost maximal within 30 s after ligand binding. The lipid kinase was identified as a type I PI 3'-kinase on the basis of its inhibition by Nonidet P-40 and high pressure liquid chromatography of the phosphorylated product. To confirm the identification of PI 3'-kinase as an effector of Neu, we raised antibodies to the alpha-isoform of the regulatory subunit of PI 3'-kinase (p85). Using these antibodies, it was possible to directly demonstrate ligand-dependent formation of a tyrosine-phosphorylated complex of NEC and PI 3'-kinase. Apparently, both PI 3'-kinase and phospholipase C gamma, another substrate of the Neu kinase, simultaneously associated with the same activated NEC molecule. Nevertheless, immunofluorescence localization of PI 3'-kinase revealed no significant cellular redistribution of the enzyme after activation of the Neu kinase. Interestingly, PI 3'-kinase was localized primarily to the cell nucleus and to confined regions of the plasma membrane. Analysis of mutants of the Neu protein indicated that the oncogenic point-mutated Neu (Glu664) was permanently coupled to PI 3'-kinase; but two nontransforming versions of the oncoprotein, a kinase-defective protein and a carboxyl-terminally deleted Neu, were devoid of the constitutive association with PI 3'-kinase. Hence, we concluded that phosphatidylinositol 3'-kinase is a physiological substrate of the Neu receptor, but the regulation of this coupling is released upon oncogenic activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351056

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Cell cycle-dependent regulation of p185neu: a relationship between disruption of this regulation and transformation.

Authors:  N Kiyokawa; D H Yan; M E Brown; M C Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

2.  Direct association of p110 beta phosphatidylinositol 3-kinase with p85 is mediated by an N-terminal fragment of p110 beta.

Authors:  P Hu; J Schlessinger
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

3.  Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1.

Authors:  Yuexing Zhang; Damilola Akinmade; Anne W Hamburger
Journal:  Cancer Lett       Date:  2008-03-19       Impact factor: 8.679

4.  Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21.

Authors:  A Orr-Urtreger; L Trakhtenbrot; R Ben-Levy; D Wen; G Rechavi; P Lonai; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

5.  Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells.

Authors:  A Chausovsky; I Tsarfaty; Z Kam; Y Yarden; B Geiger; A D Bershadsky
Journal:  Mol Biol Cell       Date:  1998-11       Impact factor: 4.138

6.  Interactions between SH2 domains and tyrosine-phosphorylated platelet-derived growth factor beta-receptor sequences: analysis of kinetic parameters by a novel biosensor-based approach.

Authors:  G Panayotou; G Gish; P End; O Truong; I Gout; R Dhand; M J Fry; I Hiles; T Pawson; M D Waterfield
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

7.  Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members.

Authors:  P Fedi; J H Pierce; P P di Fiore; M H Kraus
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

Review 8.  Inhibitors of phosphatidylinositol signalling as antiproliferative agents.

Authors:  G Powis; D Phil
Journal:  Cancer Metastasis Rev       Date:  1994-03       Impact factor: 9.264

9.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.

Authors:  S P Soltoff; K L Carraway; S A Prigent; W G Gullick; L C Cantley
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

10.  LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.

Authors:  M E Montañez-Wiscovich; D D Seachrist; M D Landis; J Visvader; B Andersen; R A Keri
Journal:  Oncogene       Date:  2009-08-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.